U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C14H16N2O2
Molecular Weight 244.289
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ETOMIDATE

SMILES

CCOC(=O)C1=CN=CN1[C@H](C)C2=CC=CC=C2

InChI

InChIKey=NPUKDXXFDDZOKR-LLVKDONJSA-N
InChI=1S/C14H16N2O2/c1-3-18-14(17)13-9-15-10-16(13)11(2)12-7-5-4-6-8-12/h4-11H,3H2,1-2H3/t11-/m1/s1

HIDE SMILES / InChI

Molecular Formula C14H16N2O2
Molecular Weight 244.289
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/mesh/68005045 | https://www.ncbi.nlm.nih.gov/pubmed/21263301 | https://academic.oup.com/bjaed/article/6/2/49/305039/The-molecular-mechanisms-of-general-anaesthesia

Etomidate (AMIDATE®) is an imidazole derivative anesthetic and hypnotic with little effect on blood gases, ventilation, or the cardiovascular system. It is intended for the induction of general anesthesia by intravenous injection. Etomidate (AMIDATE®) is also indicated for the supplementation of subpotent anesthetic agents, such as nitrous oxide in oxygen, during maintenance of anesthesia for short operative procedures such as dilation and curettage or cervical conization. It also produces a unique toxicity among anesthetic drugs - inhibition of adrenal steroid synthesis that far outlasts its hypnotic action and that may reduce survival of critically ill patients. The major molecular targets mediating anesthetic effects of etomidate (AMIDATE®) in the central nervous system are specific gamma-aminobutyric acid (GABA) type A receptor subtypes. The R(+) isomer of etomidate is 10 times more potent than its S(-) isomer at potentiating GABA-A receptor activity.

CNS Activity

Curator's Comment: Etomidate is supposed to be neuroprotective.

Originator

Curator's Comment: # Janssen Pharmaceuticals, a division of Ortho-McNeil-Jannsen Pharmaceuticals

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
AMIDATE

Approved Use

Etomidate injection, USP is indicated by intravenous injection for the induction of general anesthesia. When considering use of etomidate, the usefulness of its hemodynamic properties (see CLINICAL PHARMACOLOGY) should be weighed against the high frequency of transient skeletal muscle movements (see ADVERSE REACTIONS). Intravenous etomidate is also indicated for the supplementation of subpotent anesthetic agents, such as nitrous oxide in oxygen, during maintenance of anesthesia for short operative procedures such as dilation and curettage or cervical conization.

Launch Date

4.00204792E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
87 ng/mL
25 mg 1 times / day multiple, oral
dose: 25 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ETOMIDATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
3263 ng × min/mL
25 mg 1 times / day multiple, oral
dose: 25 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ETOMIDATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
75 min
25 mg 1 times / day multiple, oral
dose: 25 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ETOMIDATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer







Drug as perpetrator​Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Some experience of the use of etomidate in children.
1976
A comparative study of etomidate and methohexital as induction agents for analgesic anesthesia.
1976
Total intravenous anesthesia with etomidate. III. Some observations in adults.
1977
Respiratory effects of etomidate.
1977 Mar
Venous complications after intravenous injection of diazepam, flunitrazepam, thiopentone and etomidate.
1980 Jun
Etomidate: a foreshortened clinical trial.
1980 Nov
Epileptiform seizures during prolonged etomidate sedation.
1983 Aug 27
Cardiac complications during use of etomidate.
1983 Dec
[Etomidate in Intralipid. A solution for pain-free injection].
1983 Oct
Venous reactions following etomidate.
1984 Aug
Alfentanil in minor gynaecological surgery: use with etomidate and a comparison with halothane.
1984 Aug
Venous sequelae following the injection of etomidate or thiopentone i.v.
1984 Feb
The prevention of etomidate-induced myoclonus.
1984 Jan
[Alfentanil in routine clinical use. A study of 50 patients].
1985 Jan
[Increased tendency to seizures as affected by long-term infusions of etomidate in delirium tremens].
1985 Sep
Myoclonus on recovery from etomidate.
1985 Sep
[Increase in somatosensory evoked potentials during anesthesia induction with etomidate].
1986 Jun
Hypertension during anaesthesia with monoamine oxidase inhibitors.
1987 Jun
Etomidate infusions for the control of refractory status epilepticus.
1989
[A new formulation of etomidate in lipid emulsion--bioavailability and venous provocation].
1989 Aug
[Anesthesia for cardioversion. A comparison of propofol and etomidate].
1990 May-Jun
[Etomidate using a new solubilizer. Experimental clinical studies on venous tolerance and bioavailability].
1990 Oct
Acute toxicosis in two dogs associated with etomidate-propylene glycol infusion.
1994 Dec
Focal cerebral ischemia during anesthesia with etomidate, isoflurane, or thiopental: a comparison of the extent of cerebral injury.
1995 Oct
Cerebral hypoxia after etomidate administration and temporary cerebral artery occlusion.
1997 Oct
An unexpected arousal effect of etomidate in a patient on high-dose steroids.
1998 Dec
Anesthesia sensitivity in mice that lack the beta3 subunit of the gamma-aminobutyric acid type A receptor.
1998 Mar
Vascular effects of etomidate administered for electroencephalographic burst suppression in humans.
1998 Oct
Reducing myoclonus after etomidate.
1999 Jan
Solvent for etomidate may cause pain and adverse effects.
1999 Sep
The safety of etomidate for emergency rapid sequence intubation of pediatric patients.
2000 Feb
Deletion of the alpha1 or beta2 subunit of GABAA receptors reduces actions of alcohol and other drugs.
2003 Jan
Myoclonus associated with etomidate for ED procedural sedation and analgesia.
2003 Nov
Etomidate versus pentobarbital for sedation of children for head and neck CT imaging.
2004 Aug
Magnesium sulfate pretreatment reduces myoclonus after etomidate.
2005 Sep
BIS during etomidate-induced myoclonus.
2006 Apr
Alpha5GABAA receptors mediate the amnestic but not sedative-hypnotic effects of the general anesthetic etomidate.
2006 Apr 5
Etomidate versus midazolam for procedural sedation in pediatric outpatients: a randomized controlled trial.
2006 Oct
Randomized clinical trial of etomidate versus propofol for procedural sedation in the emergency department.
2007 Jan
Pretreatment of rocuronium reduces the frequency and severity of etomidate-induced myoclonus.
2008 Dec
A comparison of midazolam with remifentanil for the prevention of myoclonic movements following etomidate injection.
2008 Jan-Feb
Lidocaine pretreatment reduces the frequency and severity of myoclonus induced by etomidate.
2010 Apr
Epileptic seizure during anaesthesia induction with etomidate.
2010 Jun
Does lidocaine more effectively prevent pain upon induction with propofol or etomidate when given preemptively than when mixed with the drug?
2010 Nov
Prevention of etomidate-induced myoclonus: which is superior: Fentanyl, midazolam, or a combination? A Retrospective comparative study.
2014 Feb 16
Patents

Sample Use Guides

Etomidate (AMIDATE®) is intended for administration only by the intravenous route. The dose for induction of anesthesia in adult patients will vary between 0.2 and 0.6 mg/kg of body weight, and it must be individualized in each case. The usual dose for induction in these patients is 0.3 mg/kg, injected over a period of 30 to 60 seconds.
Route of Administration: Intravenous
In Vitro Use Guide
The effect of etomidate on GABA-A receptor function was studied in cultured rat hippocampal neurons. At a clinically relevant concentration of 4.1 microM, etomidate shifts the GABA dose response to the left (ED50 shift from 10.2 to 5.2 microM), with no change in the maximum current evoked by saturating concentrations of GABA. At a higher concentration of 82 microM, etomidate directly induces current in the absence of GABA. Analysis of single channels opened by GABA indicates that 8.2 microM etomidate increases the probability of channels being open 13-fold and increases the effective channel open time two-fold.
Substance Class Chemical
Created
by admin
on Wed Jul 05 23:03:32 UTC 2023
Edited
by admin
on Wed Jul 05 23:03:32 UTC 2023
Record UNII
Z22628B598
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ETOMIDATE
EP   INN   MART.   MI   ORANGE BOOK   USAN   USP-RS   VANDF   WHO-DD  
USAN   INN  
Official Name English
AMIDATE
Brand Name English
(+)-ETHYL 1-(.ALPHA.-METHYLBENZYL)IMIDAZOLE-5-CARBOXYLATE
Systematic Name English
etomidate [INN]
Common Name English
IMIDAZOLE-5-CARBOXYLIC ACID, 1-(.ALPHA.-METHYLBENZYL)-, ETHYL ESTER, (R)-(+)-
Systematic Name English
ETOMIDATE [ORANGE BOOK]
Common Name English
ETOMIDATE [EP MONOGRAPH]
Common Name English
ETOMIDATE [USAN]
Common Name English
ETOMIDATE [VANDF]
Common Name English
Etomidate [WHO-DD]
Common Name English
NSC-759160
Code English
HYPNOMIDATE
Brand Name English
ETOMIDATE [USP MONOGRAPH]
Common Name English
1H-IMIDAZOLE-5-CARBOXYLIC ACID, 1-(1-PHENYLETHYL)-, ETHYL ESTER, (+)-
Common Name English
ETOMIDATE [MART.]
Common Name English
ETOMIDATE [USP-RS]
Common Name English
ETOMIDATE [MI]
Common Name English
Classification Tree Code System Code
WHO-ATC N01AX07
Created by admin on Wed Jul 05 23:03:32 UTC 2023 , Edited by admin on Wed Jul 05 23:03:32 UTC 2023
WHO-VATC QN01AX07
Created by admin on Wed Jul 05 23:03:32 UTC 2023 , Edited by admin on Wed Jul 05 23:03:32 UTC 2023
NDF-RT N0000175681
Created by admin on Wed Jul 05 23:03:32 UTC 2023 , Edited by admin on Wed Jul 05 23:03:32 UTC 2023
NCI_THESAURUS C245
Created by admin on Wed Jul 05 23:03:32 UTC 2023 , Edited by admin on Wed Jul 05 23:03:32 UTC 2023
NDF-RT N0000175975
Created by admin on Wed Jul 05 23:03:32 UTC 2023 , Edited by admin on Wed Jul 05 23:03:32 UTC 2023
Code System Code Type Description
DRUG CENTRAL
1109
Created by admin on Wed Jul 05 23:03:32 UTC 2023 , Edited by admin on Wed Jul 05 23:03:32 UTC 2023
PRIMARY
EPA CompTox
DTXSID5023033
Created by admin on Wed Jul 05 23:03:32 UTC 2023 , Edited by admin on Wed Jul 05 23:03:32 UTC 2023
PRIMARY
RXCUI
4177
Created by admin on Wed Jul 05 23:03:32 UTC 2023 , Edited by admin on Wed Jul 05 23:03:32 UTC 2023
PRIMARY RxNorm
CAS
33125-97-2
Created by admin on Wed Jul 05 23:03:32 UTC 2023 , Edited by admin on Wed Jul 05 23:03:32 UTC 2023
PRIMARY
IUPHAR
5463
Created by admin on Wed Jul 05 23:03:32 UTC 2023 , Edited by admin on Wed Jul 05 23:03:32 UTC 2023
PRIMARY
FDA UNII
Z22628B598
Created by admin on Wed Jul 05 23:03:32 UTC 2023 , Edited by admin on Wed Jul 05 23:03:32 UTC 2023
PRIMARY
MERCK INDEX
M5196
Created by admin on Wed Jul 05 23:03:32 UTC 2023 , Edited by admin on Wed Jul 05 23:03:32 UTC 2023
PRIMARY Merck Index
NCI_THESAURUS
C47527
Created by admin on Wed Jul 05 23:03:32 UTC 2023 , Edited by admin on Wed Jul 05 23:03:32 UTC 2023
PRIMARY
RS_ITEM_NUM
1268750
Created by admin on Wed Jul 05 23:03:32 UTC 2023 , Edited by admin on Wed Jul 05 23:03:32 UTC 2023
PRIMARY
ECHA (EC/EINECS)
251-385-9
Created by admin on Wed Jul 05 23:03:32 UTC 2023 , Edited by admin on Wed Jul 05 23:03:32 UTC 2023
PRIMARY
DAILYMED
Z22628B598
Created by admin on Wed Jul 05 23:03:32 UTC 2023 , Edited by admin on Wed Jul 05 23:03:32 UTC 2023
PRIMARY
PUBCHEM
667484
Created by admin on Wed Jul 05 23:03:32 UTC 2023 , Edited by admin on Wed Jul 05 23:03:32 UTC 2023
PRIMARY
MESH
D005045
Created by admin on Wed Jul 05 23:03:32 UTC 2023 , Edited by admin on Wed Jul 05 23:03:32 UTC 2023
PRIMARY
ChEMBL
CHEMBL681
Created by admin on Wed Jul 05 23:03:32 UTC 2023 , Edited by admin on Wed Jul 05 23:03:32 UTC 2023
PRIMARY
EVMPD
SUB07330MIG
Created by admin on Wed Jul 05 23:03:32 UTC 2023 , Edited by admin on Wed Jul 05 23:03:32 UTC 2023
PRIMARY
WIKIPEDIA
ETOMIDATE
Created by admin on Wed Jul 05 23:03:32 UTC 2023 , Edited by admin on Wed Jul 05 23:03:32 UTC 2023
PRIMARY
NSC
759160
Created by admin on Wed Jul 05 23:03:32 UTC 2023 , Edited by admin on Wed Jul 05 23:03:32 UTC 2023
PRIMARY
SMS_ID
100000082107
Created by admin on Wed Jul 05 23:03:32 UTC 2023 , Edited by admin on Wed Jul 05 23:03:32 UTC 2023
PRIMARY
CHEBI
4910
Created by admin on Wed Jul 05 23:03:32 UTC 2023 , Edited by admin on Wed Jul 05 23:03:32 UTC 2023
PRIMARY
INN
1926
Created by admin on Wed Jul 05 23:03:32 UTC 2023 , Edited by admin on Wed Jul 05 23:03:32 UTC 2023
PRIMARY
DRUG BANK
DB00292
Created by admin on Wed Jul 05 23:03:32 UTC 2023 , Edited by admin on Wed Jul 05 23:03:32 UTC 2023
PRIMARY
LACTMED
Etomidate
Created by admin on Wed Jul 05 23:03:32 UTC 2023 , Edited by admin on Wed Jul 05 23:03:32 UTC 2023
PRIMARY
Related Record Type Details
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY